FDA approves use of bevacizumab for patients whose colorectal cancer has worsened despite previous treatment with the drug
Source: Reuters Area: News The FDA has approved the use of bevacizumab for patients whose colorectal cancer has worsened despite previous treatment with the drug. The new use will allow patients first treated with bevacizumab plus chemotherapy to be treated again with it in combination with a different chemotherapy regimen. The clinical data to support this indication come from the phase 3 ML18147 study in 820 patients with unresectable metastatic colorectal cancer progressing up to 3 months after discontinuing first-line bevacizumab plus chemotherapy. They were randomised to second-line chemotherapy with (n= 409) or without (= 411) bevacizumab 2.5 mg/kg per week equivalent (either 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks, IV). The choice between oxaliplatin-based or irinotecan-based second-line chemotherapy depended on the first-line regimen (switch of chemotherapy). The study reported that maintenance of VEGF inhibition with bevacizumab plus standard second-line chemotherapy beyond ...
ConclusionsThis case highlights the importance of recognizing gastrointestinal complications following chemotherapy and the need to be aware of the possibility of bowel perforation. Prompt surgical review and intervention must be requested in patients with acute abdominal pain and persistent gastrointestinal symptoms such as diarrhea and vomiting.
Authors: Oweira H, Abdel-Rahman O, Giryes A, Mannhart M, Decker M Abstract BACKGROUND: Time to start adjuvant therapy has been shown to be an important determinant of survival following curative resection of colorectal cancer. Time to start systemic therapy following diagnosis of metastatic colorectal cancer (mCRC) needs to be additionally studied and assessed. METHODS: This is a pooled analysis of the raw data of the comparator arms of two randomized studies (NCT00272051; NCT00305188). Univariate and Multivariate analysis of predictors of overall and progression-free survival was conducted through Cox regressi...
The chemotherapy dripped through a catheter in his chest. Cancer patient Robert Goodman had burned through his paid sick days while undergoing surgery and chemotherapy for colon cancer.
The irinotecan-induced phosphokinome changes in colorectal cancer (CRC) cells were used to guide the selection of targeted agents to be tested in combination with irinotecan.
The objective of this review is to present insights into pharmacotherapeutic techniques, which can be used for transdermal delivery of anticancer agents through skin due to its potential to create a new frontier in treatment of cancer. PMID: 30095010 [PubMed - as supplied by publisher]
International Journal of Cancer, EarlyView.
ConclusionAdministration of adjuvant chemotherapy for stage II/III colon cancer decreases with advancing age, but improved outcomes are seen in stage III patients under 90 years of age.
CONCLUSIONS: The recurrence rate is less than that previously observed in historical materials, but current, commonly used risk factors are still useful in evaluating recurrence risks. Stratification by pT and pN classification and the number of risk factors enables the identification of large patient groups characterized by such a low recurrence rate that it is questionable whether adjuvant treatment is motivated. See Video Abstract at http://links.lww.com/DCR/A663.
CONCLUSIONS: A history of extraperitoneal disease is associated with poorer prognosis. However, survival benefit may be obtained in selected patients with limited peritoneal involvement. See Video Abstract at http://links.lww.com/DCR/A655.
Abstract BACKGROUND: Scant real-world data exist on the clinical outcomes associated with the use of bevacizumab-containing chemotherapy (B+CT) in patients with metastatic colorectal cancer (mCRC). The primary objective of the GRETA cohort study was to compare the overall survival (OS) of patients with mCRC treated with first-line B+CT versus chemotherapy (CT) alone, in an Italian clinical practice setting. MATERIALS AND METHODS: Incident patients with mCRC were identified during the period 2010-2012 from five population-based cancer registries in Italy. Cases were linked to regional health care utilization d...